CN109705222A - The fusion protein and the preparation method and application thereof of flaviviridae envelope protein - Google Patents

The fusion protein and the preparation method and application thereof of flaviviridae envelope protein Download PDF

Info

Publication number
CN109705222A
CN109705222A CN201811613477.1A CN201811613477A CN109705222A CN 109705222 A CN109705222 A CN 109705222A CN 201811613477 A CN201811613477 A CN 201811613477A CN 109705222 A CN109705222 A CN 109705222A
Authority
CN
China
Prior art keywords
ser
gly
val
thr
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811613477.1A
Other languages
Chinese (zh)
Inventor
龚睿
杨春鹏
曾芳
高新宇
张哲�
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuhan Institute of Virology of CAS
Original Assignee
Wuhan Institute of Virology of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuhan Institute of Virology of CAS filed Critical Wuhan Institute of Virology of CAS
Priority to CN201811613477.1A priority Critical patent/CN109705222A/en
Publication of CN109705222A publication Critical patent/CN109705222A/en
Pending legal-status Critical Current

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention discloses a kind of fusion proteins and the preparation method and application thereof of flaviviridae envelope protein.The present invention with antibody Fc fragment by merging flaviviridae envelope protein to obtain fusion protein, compared with flaviviridae envelope protein, has the structure closer to virus surface native conformation, can be applied to the antibody that in-vitro screening is directed to space conformation;It can also be applied to the preparation of vaccine simultaneously, induction body generates efficiently and the predicting space epitope antibody of wide spectrum, Fc segment can also enhance the response of cellular immunity.

Description

The fusion protein and the preparation method and application thereof of flaviviridae envelope protein
Technical field
The present invention relates to field of biotechnology, a kind of fusion protein in particular to flaviviridae envelope protein and its Preparation method and application.
Background technique
Zika virus (ZIKV) is a kind of flaviviridae, can lead to neonatal microcephalus simultaneously after infecting the virus The neurodevelopment of infant is influenced, Guillain Barre syndrome (GBS), which may occur, after Adult infections leads to neurotrosis.Stockaded village's card Virus mainly enters host cell by the envelope protein on its surface.In natural virus surface, zika virus envelope protein (ZE) be in the form of antiparallel dimer existing for, and some researches show that, the antibody for dimer comformational epitope is high Effect and can be in wide spectrum and zika virus and dengue fever virus.Therefore external to obtain close to flaviviridae surface cyst membrane egg The recombinant protein of white native conformation is vital for the discovery of antiviral drugs and the development of vaccine.
Summary of the invention
It is an object of the invention to be obtained in vitro closer to flaviviridae envelope protein native dimeric body conformation Recombinant protein provides the fusion protein and its system of a kind of flaviviridae envelope protein for being easily achieved external dimerization conformation Preparation Method and application.
To achieve the above object, the present invention provides a kind of fusion protein of flaviviridae envelope protein, it be by The fusion protein of the antibody Fc fragment of flaviviridae envelope protein and humanized IgG composition.
In above scheme, it is preferable that the coding gene sequence of the fusion protein is by the method for bridging PCR by jaundice The Gene Fusion of the antibody Fc fragment of the gene and humanized IgG of malicious coe virus envelope protein obtains.
In above scheme, the gene of the antibody Fc fragment of the humanized IgG passes through artificial mutation, and the mutational site is Fc The cysteine base of the hinge portion of segment.Disulfide bond is easily formed between cysteine base, is made by way of mutation The space structure for obtaining fusion protein has more freedom.
Preferably, the cysteine base mutation is the base of encoding serine.Serine is similar with cysteine, no Change the property of albumen.
The method of the present invention is passed through for the flaviviridae envelope protein for being not readily available dimerization conformation in vitro It is merged with the Fc segment of human antibody IgG, such as ZE virus and Fc segment composition, human antibody IgG-Fc segment can be by CH3 Non-covalent strong interaction between structural domain, which mediates, generates dimerization, we can form the spy of dimer by Fc segment herein Property, zika virus envelope protein is merged with Fc segment, building obtain ZE-Fc fusion protein, and thus obtain close to The recombinant protein of native dimeric body conformation obtains under the action of Fc segment native dimeric closer to the natural structure of virus surface The dimer recombinant protein of elephant.Flaviviridae is well-conserved in structure, therefore dimerization strategy provided herein It can be applied to the external reproduction of entire flaviviridae envelope protein native conformation.
The present invention also provides the fusion protein of a kind of zika virus envelope protein and Fc segment, amino acid full length sequences For Seq ID No.2, it is named as ZE-Fc.
Optionally, the coding gene sequence of the ZE and Fc fusion protein (ZE-Fc) are Seq ID No.1.
The present invention also provides the preparation method of above-mentioned zika virus envelope protein and the fusion protein of Fc segment, steps It is as follows:
(1) genetic fragment of Fc and the genetic fragment of zika virus envelope protein are prepared;The zika virus envelope protein Gene be ZE extracellular domain 1-408 amino acid coded sequence;
(2) genetic fragment of the genetic fragment of Fc and zika virus envelope protein is merged to obtain complete ZE-Fc gene;
(3) it with ZE-Fc gene order construction of expression vector, transfects, expression, purifying obtains destination protein.
In above scheme, the genetic fragment of the Fc is mutated gene, described to sport wild type Fc hinge portion Cysteine base mutation be encoding serine base, amplification obtain Fc (S.Hinge).
In above scheme, the step (3) are as follows: insect expression vector is constructed with ZE-Fc gene order, and is transfected into drosophila In S2 cell, building surely turns expression cell system, carries out eukaryotic expression, and purifying obtains destination protein.
Present invention further teaches the fusion proteins of above-mentioned flaviviridae envelope protein, are preparing antiviral antibody and epidemic disease Application in seedling.
Beneficial effects of the present invention:
(1) it is merged by the Fc segment with human antibody IgG1, under the action of Fc segment native dimeric, is obtained Closer to the dimer recombinant protein of virus surface native conformation, realizes and be not easy external Dimerized flaviviridae The native conformation of envelope protein reappears.
(2) relative to the flaviviridae envelope protein directly expressed, fusion protein can pass through Fc fragment mediates Cellullar immunologic response causes stronger vivo immunization reaction, this lays a good foundation for it as vaccine dose.
(3) retaining for the fusion protein of zika virus envelope protein and Fc segment relative to the ZE directly expressed In the case where ZE monomer conformation, the structure of antiparallel dimer has also been reappeared.
Detailed description of the invention
Fig. 1 is protein immunoblot detection figure after the expression and purification of ZE and ZE-Fc albumen.
Fig. 2 is SDS electrophoretogram after the expression and purification of ZE and ZE-Fc albumen.
Fig. 3 is SDS electrophoretogram after the expression and purification of D2E-Fc and JE-Fc albumen.
Fig. 4 is the secondary structure figure of ZE and ZE-Fc albumen.
Fig. 5 is the thermal denaturation analysis chart of ZE and ZE-Fc albumen.
Fig. 6 is ZE and ZE-Fc albumen and the elisa assay figure for identifying non-space epitope-positive antibody.
Fig. 7 is ZE and ZE-Fc albumen and the elisa assay figure for identifying predicting space epitope positive antibody.
Fig. 8 is after mouse is immunized respectively in ZE and ZE-Fc albumen, and antibody generates the elisa assay figure of titre in mice serum Wherein it is directed to the antibody titer analysis chart of predicting space epitope.
Specific embodiment
Below in conjunction with the drawings and specific embodiments, the present invention is described in further detail.Following embodiment is with this Implemented under premised on inventive technique scheme, the detailed implementation method and specific operation process are given, but of the invention Protection scope is not limited to the following embodiments.
Embodiment 1: amplification ZE and ZE-Fc fragment gene
According to it has been reported that ZE gene order (GenBank:KJ776791) and humanized IgG 1 Fc fragment gene sequence (GenBank:KJ905798.1), gene chemical synthesis is carried out according to Drosophila S 2 cells codon bias, will when synthesis The sequence of TwinStrep-tag is added in the c-terminus of ZE and Fc base, and designs forward and reverse primer according to the base sequence of synthesis Expand target fragment:
Forward primer
5-AGATCTCCATGG(horizontal line is labeled as NcoI digestion to ATCCGTTGCATCGGCGTGTCCAACCGTGAC-3 (1) Site)
5-GAACCAAAAAGCAGCGATAAG-3(2);
Reverse primer
5-CTAGA CTCGAG(horizontal line is labeled as Xho I digestion position to TTA CTTCTCAAACTGCGGGTGGCT-3 (1) Point)
PCR is carried out with forward primer (1)/(2) and reverse primer (1) by template of the base sequence of synthesis respectively, respectively ZE and Fc genetic fragment is obtained, and carries out bridging PCR using forward primer (1) and reverse primer (1), obtains ZE-Fc gene.
Agarose gel electrophoresis recycles ZE-Fc genetic fragment, with Nco I and Xho I digestion ZE-Fc gene and carrier pMT- ZE-Fc gene is connect, Transformed E .coliTop10 competence by Bip-V5-His after glue recycling with carrier pMT-Bip-V5-His, Subsequent picking monoclonal send sequencing.According to sequencing result, the correct monoclonal of picking sequence is used for subsequent experimental.
The gene order of ZE-Fc are as follows: Seq ID No.1, the amino acid sequence of coding are Seq ID No.2.
Embodiment 2: the S2 cell line of building stable transfection expression ZE-Fc/ZE albumen
The S2 that ZE-Fc/ZE plasmid and screening plasmid pCoBlast are gone to adhere-wall culture using Effectene kit is thin Born of the same parents, by the screening of about 20 days Blasticidin resistances, obtain adherent growth surely turns S2 cell line, through serum free medium After adaptation, freezes a batch and surely turn S2 cell line, and remaining cell is gone into 40ml shaking flask further expansion culture, be turning finally to In the Tissue Culture Flask of 1L, and final concentration of 500 μM of CuSO is added4The expression of solution inducible protein is shaken in 27 DEG C, 100rpm Bed culture 8-10 days.
Then, centrifugation (6000g, 4 DEG C, 15min) collects S2 cell conditioned medium (supernatant is with the StrepTactin that HRP is marked It detects antibody and carries out protein immunoblot detection, as a result as shown in Figure 1, being filled out after the supernatant of collection is filtered with StrepTactin Expect that (IBA company) purifies ZE, ZE-Fc albumen.It is then carried out with molecular sieve secondarily purified, and is 10kD using molecular cut off Target protein is concentrated by ultrafiltration in ultra-filtration centrifuge tube (Merck Millipore company), its purity is verified through SDS-PAGE, such as Fig. 2 institute Show, the swimming lane of right figure from left to right is respectively as follows: Marker, ZE-Fc (boiling sample) and ZE-Fc (not boiling sample).It can be found that ZE-Fc melts Hop protein can form dimer by the noncovalent interaction of Fc segment.
The dimerization situation of embodiment 3:D2E-Fc and JE-Fc
In order to which other are not easy with obtain the flaviviridae envelope protein of dimerization conformation in vitro, we are also utilized with real The method of example 1 and 2 is applied to obtain fusion protein, and is verified.
Two type dengue virus envelope proteins (D2E), gene order (GenBank:KM087965.1), fusion protein are D2E-Fc, amino acid sequence be Seq ID No.3 japanese encephalitis virus envelope protein (JE), gene order (GenBank: FJ938228.1), fusion protein JE-Fc, amino acid sequence are Seq ID No.4
After expression and purification, the formational situation of dimer is demonstrated to the further SDS-PAGE of D2E-Fc and JE-Fc, such as Shown in Fig. 3, swimming lane from left to right is successively are as follows: Marker, D2E-Fc (boiling sample), D2E-Fc (not boiling sample), JE-Fc (boiling sample) and JE-Fc (does not boil sample).
The secondary structure and thermal stability analysis of embodiment 4:ZE, ZE-Fc albumen
The secondary structure of albumen is measured using circular dichroism spectrometer (CD) and carries out thermal stability analysis.Protein concentration is adjusted It is added in 0.1cm cuvette to 0.3-0.4mg/ml, and after being filtered with 0.22 μm of filter membrane, under the conditions of 25 DEG C, near ultraviolet end (190-260nm) respectively to air, PBS, protein sample is scanned measurement, every data of 0.5 second record.Experiment setting It is repeated twice, the reading that PBS is reduced after being averaged is the protein data of measurement.As a result as shown in figure 4, according to analysis, this The secondary structure of two albumen is typical beta sheet, it was demonstrated that second level knot of the introducing of Fc segment without change ZE albumen itself Structure.
The temperature range that thermal stability analysis selects is 25~95 DEG C, and experiment initial temperature is 25 DEG C, by 0.5 DEG C/min's Rate increases temperature, every 0.5s detection protein to the absorption of circularly polarized light at 216nm wavelength.According to alternating temperature temperature and egg White mean residue ellipticity MRE mapping, can analyze the thermal stability for comparing albumen and solution temperature Tm (melting temperature).As a result as shown in figure 5, apparent three-stage unfolding process is presented in ZE-Fc albumen, wherein ZE section and ZE egg Influence in terms of white unfolding process is similar, and Tm value is also roughly the same, therefore Fc fusion protein will not have stability to ZE.
Embodiment 5:ELISA analyzes identification of the positive antibody to ZE, ZE-Fc albumen
According to reported antigen antibody complex structure, it is anti-that positive antibody can be divided into identification non-space structure epi-position Body and identification space structure epitope antibodies.Non-space structure epi-position: 2A10G6 (PDB 5JHL), ZV-67 (PDB 5KVG);Space Structure epi-position: EDE2 A11 (PDB 5LCV), EDE2 B7 (PDB 4UT6), EDE1 C10 (PDB 4UT9).It is coated with ZE and ZE- Fc albumen uses 2A10G6 and ZV-67 as primary antibody on elisa plate, and the Anti-His for using HRP to mark develops the color as secondary antibody As a result as shown in fig. 6, non-space structure epi-position can be identified effectively, and the EC50 of ZE-Fc albumen is higher.In space structure Epitope identification aspect is coated with StrepTactin albumen on elisa plate as capture antibody, ZE and ZE-Fc albumen is then added As antigen, the positive antibody of gradient dilution is as primary antibody, and the anti-Fab for using HRP to mark is as secondary antibody, and develop the color result such as Fig. 7 Shown, only ZE-Fc can preferably be identified that ZE does not show ELISA signal.Therefore ZE-Fc recombinant protein being capable of body The outer structure reappeared close to virus surface native dimeric body conformation.
The mouse immune of embodiment 6:ZE-Fc albumen
Fusion protein ZE-Fc and ZE are uniformly mixed with QuickAntibody adjuvant (Biodragon) respectively, albumen is whole Concentration is 0.2mg/ml.The female BABL/c mouse of 4-6 week old is divided into 3 groups, every group 5, respectively with 100 μ l fusion proteins ZE-Fc and recombinant protein ZE are injected at the hind leg muscle of mouse, and PBS is as negative control.Exempted from for the second time after three weeks Epidemic disease took certain serum from mouse orbit veniplex after 2 weeks, measured antibody titer therein with ELISA method;Meanwhile benefit Whether ELISA means (capture ELISA and indirect ELISA) verifying differently wherein produces for the anti-of predicting space epitope Body.As a result as shown in figure 8, mouse, which is immunized, with fusion protein ZE-Fc and ZE can generate antibody, but fusion protein ZE-Fc is induced The antibody titer of generation is apparently higher than ZE, and since fusion protein ZE-Fc remains predicting space epitope structure, only immune The mouse of fusion protein ZE-Fc produces the antibody for predicting space epitope.According to existing report, for the antibody of predicting space epitope Can very effective neutralization virus, therefore, fusion protein ZE-Fc is expected to become effective subunit vaccine.
Sequence table
<110>Wuhan Virology Institute,Chinan academy of Sciences
<120>fusion protein and the preparation method and application thereof of flaviviridae envelope protein
<130> 2018
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 2025
<212> DNA
<213> ZE-Fc
<400> 1
atccgttgca tcggcgtgtc caaccgtgac ttcgtcgagg gaatgagcgg cggaacgtgg 60
gtggatgtgg tgctggagca cggaggctgc gtgaccgtca tggcccagga taagcccacc 120
gtggatatcg agctggtgac cacgaccgtg tccaacatgg ccgaggtgcg ttcctactgc 180
tacgaggcct ccatctccga catggccagc gactcccgtt gccccaccca aggagaggcc 240
tacttggaca agcagtccga cacccagtac gtgtgcaagc gcaccctggt ggaccgtgga 300
tggggcaacg gctgcggatt gttcggcaag ggaagcctgg tgacgtgcgc taagttcgcc 360
tgcagcaaga agatgaccgg caagagcatc cagcccgaga atctggagta ccgcatcatg 420
ctgtccgtcc acggctccca gcactccggc atgatcgtga acgacaccgg ccacgaaacc 480
gacgagaatc gcgccaaggt ggagattacc ccgaattccc cccgcgctga ggccaccttg 540
ggcggctttg gctccctggg actggattgc gagccgcgca ccggattgga cttcagcgac 600
ctgtactatc tgaccatgaa caacaagcac tggctggtcc ataaggagtg gttccacgac 660
atccccctgc cgtggcatgc cggagccgat accggaaccc cccactggaa caacaaggag 720
gccctggtgg agttcaagga tgcccatgcc aagcgccaga ccgtggtcgt gctgggctcc 780
caggagggag ctgtgcatac cgctctggcc ggagctctgg aggccgaaat ggatggcgcc 840
aagggccgcc tgtccagcgg acatctgaag tgccgcctga agatggacaa gctgcgcctg 900
aagggcgtgt cctacagcct gtgcaccgct gccttcacct tcacgaagat ccccgctgag 960
accctgcacg gaaccgtgac cgtggaggtg cagtacgctg gcacggatgg cccgtgtaag 1020
gtgcccgccc agatggccgt ggatatgcaa acgctgaccc ccgtgggacg cctgattacc 1080
gccaacccgg tcatcaccga gtccacggag aacagcaaga tgatgttgga gttggatccc 1140
ccgttcggcg acagctacat tgtgatcggc gtgggagaga agaagatcac ccaccattgg 1200
caccgcagcg gcagcaccat tggcgaacca aaaagcagcg ataagaccca caccagcccc 1260
ccaagcccag ctccagaatt gctgggaggc ccaagcgtgt ttctgtttcc ccccaaaccc 1320
aaggataccc tgatgataag ccgaaccccc gaagtgacgt gcgtggttgt ggatgtgagc 1380
cacgaggatc ccgaggtgaa attcaactgg tacgtggatg gcgtcgaggt gcacaacgcc 1440
aagaccaaac cccgcgagga acaatataac tcgacctacc gcgtggtgag cgtgttgacc 1500
gtgctgcatc aggattggct caacggcaag gagtacaagt gcaaggtgtc caacaaagcc 1560
ctgcccgccc ctatcgagaa aaccatcagc aaggccaagg gacagccacg cgagccacaa 1620
gtttacacac tgccccccag ccgtgatgaa ctgaccaaga accaggtgag cctgacctgc 1680
ctcgtgaaag gcttctaccc cagcgatatc gccgtggagt gggagagtaa cggccagcca 1740
gagaacaact acaaaacaac cccccccgtc ctcgatagcg atggaagttt cttcctgtac 1800
agtaaactga ccgtggataa aagccgctgg cagcagggca atgtgttcag ctgctccgtg 1860
atgcacgagg ccctccataa ccactacacc cagaaaagcc tgagcctgag ccccggaaag 1920
gacgatgacg ataagagcgc ctggagccac ccccaattcg aaaagggcgg cggttcggga 1980
ggcggaagtg gaggaagtgc ttggagccac ccgcagtttg agaag 2025
<210> 2
<211> 675
<212> PRT
<213> ZE-Fc
<400> 2
Ile Arg Cys Ile Gly Val Ser Asn Arg Asp Phe Val Glu Gly Met Ser
1 5 10 15
Gly Gly Thr Trp Val Asp Val Val Leu Glu His Gly Gly Cys Val Thr
20 25 30
Val Met Ala Gln Asp Lys Pro Thr Val Asp Ile Glu Leu Val Thr Thr
35 40 45
Thr Val Ser Asn Met Ala Glu Val Arg Ser Tyr Cys Tyr Glu Ala Ser
50 55 60
Ile Ser Asp Met Ala Ser Asp Ser Arg Cys Pro Thr Gln Gly Glu Ala
65 70 75 80
Tyr Leu Asp Lys Gln Ser Asp Thr Gln Tyr Val Cys Lys Arg Thr Leu
85 90 95
Val Asp Arg Gly Trp Gly Asn Gly Cys Gly Leu Phe Gly Lys Gly Ser
100 105 110
Leu Val Thr Cys Ala Lys Phe Ala Cys Ser Lys Lys Met Thr Gly Lys
115 120 125
Ser Ile Gln Pro Glu Asn Leu Glu Tyr Arg Ile Met Leu Ser Val His
130 135 140
Gly Ser Gln His Ser Gly Met Ile Val Asn Asp Thr Gly His Glu Thr
145 150 155 160
Asp Glu Asn Arg Ala Lys Val Glu Ile Thr Pro Asn Ser Pro Arg Ala
165 170 175
Glu Ala Thr Leu Gly Gly Phe Gly Ser Leu Gly Leu Asp Cys Glu Pro
180 185 190
Arg Thr Gly Leu Asp Phe Ser Asp Leu Tyr Tyr Leu Thr Met Asn Asn
195 200 205
Lys His Trp Leu Val His Lys Glu Trp Phe His Asp Ile Pro Leu Pro
210 215 220
Trp His Ala Gly Ala Asp Thr Gly Thr Pro His Trp Asn Asn Lys Glu
225 230 235 240
Ala Leu Val Glu Phe Lys Asp Ala His Ala Lys Arg Gln Thr Val Val
245 250 255
Val Leu Gly Ser Gln Glu Gly Ala Val His Thr Ala Leu Ala Gly Ala
260 265 270
Leu Glu Ala Glu Met Asp Gly Ala Lys Gly Arg Leu Ser Ser Gly His
275 280 285
Leu Lys Cys Arg Leu Lys Met Asp Lys Leu Arg Leu Lys Gly Val Ser
290 295 300
Tyr Ser Leu Cys Thr Ala Ala Phe Thr Phe Thr Lys Ile Pro Ala Glu
305 310 315 320
Thr Leu His Gly Thr Val Thr Val Glu Val Gln Tyr Ala Gly Thr Asp
325 330 335
Gly Pro Cys Lys Val Pro Ala Gln Met Ala Val Asp Met Gln Thr Leu
340 345 350
Thr Pro Val Gly Arg Leu Ile Thr Ala Asn Pro Val Ile Thr Glu Ser
355 360 365
Thr Glu Asn Ser Lys Met Met Leu Glu Leu Asp Pro Pro Phe Gly Asp
370 375 380
Ser Tyr Ile Val Ile Gly Val Gly Glu Lys Lys Ile Thr His His Trp
385 390 395 400
His Arg Ser Gly Ser Thr Ile Gly Glu Pro Lys Ser Ser Asp Lys Thr
405 410 415
His Thr Ser Pro Pro Ser Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
420 425 430
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
435 440 445
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
450 455 460
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
465 470 475 480
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
485 490 495
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
500 505 510
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
515 520 525
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
530 535 540
Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys
545 550 555 560
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
565 570 575
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
580 585 590
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
595 600 605
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
610 615 620
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
625 630 635 640
Asp Asp Asp Asp Lys Ser Ala Trp Ser His Pro Gln Phe Glu Lys Gly
645 650 655
Gly Gly Ser Gly Gly Gly Ser Gly Gly Ser Ala Trp Ser His Pro Gln
660 665 670
Phe Glu Lys
675
<210> 3
<211> 658
<212> PRT
<213> D2E-Fc
<400> 3
Met Arg Cys Ile Gly Ile Ser Asn Arg Asp Phe Val Glu Gly Val Ser
1 5 10 15
Gly Gly Ser Trp Val Asp Ile Val Leu Glu His Gly Ser Cys Val Thr
20 25 30
Thr Met Ala Lys Asn Lys Pro Thr Leu Asp Phe Glu Leu Ile Lys Thr
35 40 45
Glu Ala Lys Gln Pro Ala Thr Leu Arg Lys Tyr Cys Ile Glu Ala Lys
50 55 60
Leu Thr Asn Thr Thr Thr Glu Ser Arg Cys Pro Thr Gln Gly Glu Pro
65 70 75 80
Ser Leu Asn Glu Glu Gln Asp Lys Arg Phe Ile Cys Lys His Ser Met
85 90 95
Val Asp Arg Gly Trp Gly Asn Gly Cys Gly Leu Phe Gly Lys Gly Gly
100 105 110
Ile Val Thr Cys Ala Lys Phe Thr Cys Lys Lys Asn Met Glu Gly Lys
115 120 125
Ile Val Gln Pro Glu Asn Leu Glu Tyr Thr Ile Val Ile Thr Pro His
130 135 140
Ser Gly Glu Glu His Ala Val Gly Asn Asp Thr Gly Lys His Gly Lys
145 150 155 160
Glu Ile Lys Ile Thr Pro Gln Ser Ser Thr Thr Glu Ala Glu Leu Thr
165 170 175
Gly Tyr Gly Thr Val Thr Met Glu Cys Ser Pro Arg Thr Gly Leu Asp
180 185 190
Phe Asn Glu Met Val Leu Leu Gln Met Glu Asp Lys Ala Trp Leu Val
195 200 205
His Arg Gln Trp Phe Leu Asp Leu Pro Leu Pro Trp Leu Pro Gly Ala
210 215 220
Asp Thr Gln Gly Ser Asn Trp Ile Gln Lys Glu Thr Leu Val Thr Phe
225 230 235 240
Lys Asn Pro His Ala Lys Lys Gln Asp Val Val Val Leu Gly Ser Gln
245 250 255
Glu Gly Ala Met His Thr Ala Leu Thr Gly Ala Thr Glu Ile Gln Met
260 265 270
Ser Ser Gly Asn Leu Leu Phe Thr Gly His Leu Lys Cys Arg Leu Arg
275 280 285
Met Asp Lys Leu Gln Leu Lys Gly Met Ser Tyr Ser Met Cys Thr Gly
290 295 300
Lys Phe Lys Ile Val Lys Glu Ile Ala Glu Thr Gln His Gly Thr Ile
305 310 315 320
Val Ile Arg Val Gln Tyr Glu Gly Asp Gly Ser Pro Cys Lys Ile Pro
325 330 335
Phe Glu Ile Thr Asp Leu Glu Lys Arg His Val Leu Gly Arg Leu Ile
340 345 350
Thr Val Asn Pro Ile Val Thr Glu Lys Asp Ser Pro Val Asn Ile Glu
355 360 365
Ala Glu Pro Pro Phe Gly Asp Ser Tyr Ile Ile Val Gly Val Glu Pro
370 375 380
Gly Gln Leu Lys Leu Asn Trp Glu Pro Lys Ser Ser Asp Lys Thr His
385 390 395 400
Thr Ser Pro Pro Ser Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val
405 410 415
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
420 425 430
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
435 440 445
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
450 455 460
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
465 470 475 480
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
485 490 495
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile
500 505 510
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
515 520 525
Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
530 535 540
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
545 550 555 560
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
565 570 575
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
580 585 590
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
595 600 605
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Asp
610 615 620
Asp Asp Asp Lys Ser Ala Trp Ser His Pro Gln Phe Glu Lys Gly Gly
625 630 635 640
Gly Ser Gly Gly Gly Ser Gly Gly Ser Ala Trp Ser His Pro Gln Phe
645 650 655
Glu Lys
<210> 4
<211> 671
<212> PRT
<213> JE-Fc
<400> 4
Phe Asn Cys Leu Gly Met Gly Asn Arg Asp Phe Ile Glu Gly Ala Ser
1 5 10 15
Gly Ala Thr Trp Val Asp Leu Val Leu Glu Gly Asp Gly Cys Leu Thr
20 25 30
Ile Met Ala Asn Asp Lys Pro Thr Leu Asp Val Arg Met Ile Asn Ile
35 40 45
Glu Ala Ser Gln Leu Ala Glu Val Arg Ser Tyr Cys Tyr His Ala Ser
50 55 60
Val Thr Asp Ile Ser Thr Val Ala Arg Cys Pro Thr Thr Gly Glu Ala
65 70 75 80
His Asn Glu Lys Arg Ala Asp Ser Ser Tyr Val Cys Lys Gln Gly Phe
85 90 95
Thr Asp Arg Gly Trp Gly Asn Gly Cys Gly Leu Phe Gly Lys Gly Ser
100 105 110
Ile Asp Thr Cys Ala Lys Phe Ser Cys Thr Ser Lys Ala Ile Gly Arg
115 120 125
Thr Ile Gln Pro Glu Asn Ile Lys Tyr Glu Val Gly Ile Phe Val His
130 135 140
Gly Thr Thr Thr Ser Glu Asn His Gly Asn Tyr Ser Ala Gln Val Gly
145 150 155 160
Ala Ser Gln Ala Ala Lys Phe Thr Val Thr Pro Asn Ala Pro Ser Ile
165 170 175
Thr Leu Lys Leu Gly Asp Tyr Gly Glu Val Thr Leu Asp Cys Glu Pro
180 185 190
Arg Ser Gly Leu Asn Thr Glu Ala Phe Tyr Val Met Thr Val Gly Ser
195 200 205
Lys Ser Phe Leu Val His Arg Glu Trp Phe His Asp Leu Ala Leu Pro
210 215 220
Trp Thr Ser Pro Ser Ser Thr Ala Trp Arg Asn Arg Glu Leu Leu Met
225 230 235 240
Glu Phe Glu Glu Ala His Ala Thr Lys Gln Ser Val Val Ala Leu Gly
245 250 255
Ser Gln Glu Gly Gly Leu His Gln Ala Leu Ala Gly Ala Ile Val Val
260 265 270
Glu Tyr Ser Ser Ser Val Lys Leu Thr Ser Gly His Leu Lys Cys Arg
275 280 285
Leu Lys Met Asp Lys Leu Ala Leu Lys Gly Thr Thr Tyr Gly Met Cys
290 295 300
Thr Glu Lys Phe Ser Phe Ala Lys Asn Pro Ala Asp Thr Gly His Gly
305 310 315 320
Thr Val Val Ile Glu Leu Ser Tyr Ser Gly Ser Asp Gly Pro Cys Lys
325 330 335
Ile Pro Ile Val Ser Val Ala Ser Leu Asn Asp Met Thr Pro Val Gly
340 345 350
Arg Leu Val Thr Val Asn Pro Phe Val Ala Thr Ser Ser Ala Asn Ser
355 360 365
Lys Val Leu Val Glu Met Glu Pro Pro Phe Gly Asp Ser Tyr Ile Val
370 375 380
Val Gly Arg Gly Asp Lys Gln Ile Asn His His Trp His Lys Ala Gly
385 390 395 400
Ser Thr Leu Gly Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro
405 410 415
Pro Ser Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe
420 425 430
Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
435 440 445
Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe
450 455 460
Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
465 470 475 480
Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
485 490 495
Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
500 505 510
Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
515 520 525
Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
530 535 540
Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
545 550 555 560
Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
565 570 575
Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
580 585 590
Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
595 600 605
Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
610 615 620
Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Asp Asp Asp Asp
625 630 635 640
Lys Ser Ala Trp Ser His Pro Gln Phe Glu Lys Gly Gly Gly Ser Gly
645 650 655
Gly Gly Ser Gly Gly Ser Ala Trp Ser His Pro Gln Phe Glu Lys
660 665 670

Claims (10)

1. a kind of fusion protein of flaviviridae envelope protein, it is by flaviviridae envelope protein and humanized IgG Antibody Fc fragment composition fusion protein.
2. the fusion protein of flaviviridae envelope protein according to claim 1, it is characterised in that: the fusion egg White coding gene sequence is by the method for bridging PCR by the anti-of the gene of flaviviridae envelope protein and humanized IgG The Gene Fusion of body Fc segment obtains.
3. the fusion protein of flaviviridae envelope protein according to claim 1, it is characterised in that: the source of people The gene of the antibody Fc fragment of IgG passes through artificial mutation, and the mutational site is the cysteine of the hinge portion of Fc segment Base.
4. the fusion protein of flaviviridae envelope protein according to claim 3, it is characterised in that: the half Guang ammonia Soda acid base sports the base of encoding serine.
5. a kind of fusion protein of zika virus envelope protein and Fc segment, amino acid full length sequence is Seq ID No.2.
6. the fusion protein of zika virus envelope protein and Fc segment according to claim 5, it is characterised in that: the fusion The coding gene sequence of albumen is Seq ID No.1.
7. the preparation method of zika virus envelope protein described in a kind of claim 5 and the fusion protein of Fc segment, step is such as Under:
(1) genetic fragment of Fc and the genetic fragment of zika virus envelope protein are prepared;The base of the zika virus envelope protein Because of the coded sequence of the 1-408 amino acid of ZE extracellular domain;
(2) genetic fragment of the genetic fragment of Fc and zika virus envelope protein is merged to obtain complete ZE-Fc gene;
(3) it with ZE-Fc gene order construction of expression vector, transfects, expression, purifying obtains destination protein.
8. the preparation method of zika virus envelope protein described in a kind of claim 5 and the fusion protein of Fc segment, feature exist In: the genetic fragment of the Fc is mutated gene, and described sport dashes forward the cysteine base of wild type Fc hinge portion Become the base of encoding serine.
9. the preparation method of zika virus envelope protein and the fusion protein of Fc segment, feature exist according to claim 7 In: the step (3) are as follows: insect expression vector is constructed with ZE-Fc gene order, and is transfected into Drosophila S 2 cells, building is steady Turn expression cell system, carry out eukaryotic expression, purifying obtains destination protein.
10. the fusion protein of flaviviridae envelope protein described in claim 1, in preparing antiviral antibody and vaccine Using.
CN201811613477.1A 2018-12-27 2018-12-27 The fusion protein and the preparation method and application thereof of flaviviridae envelope protein Pending CN109705222A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811613477.1A CN109705222A (en) 2018-12-27 2018-12-27 The fusion protein and the preparation method and application thereof of flaviviridae envelope protein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811613477.1A CN109705222A (en) 2018-12-27 2018-12-27 The fusion protein and the preparation method and application thereof of flaviviridae envelope protein

Publications (1)

Publication Number Publication Date
CN109705222A true CN109705222A (en) 2019-05-03

Family

ID=66258717

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811613477.1A Pending CN109705222A (en) 2018-12-27 2018-12-27 The fusion protein and the preparation method and application thereof of flaviviridae envelope protein

Country Status (1)

Country Link
CN (1) CN109705222A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110981966A (en) * 2019-11-19 2020-04-10 广州迪澳生物科技有限公司 Fusion protein for detecting Zika virus and Zika virus specific T cell detection kit
CN111100201A (en) * 2019-12-31 2020-05-05 武汉班科生物技术股份有限公司 Murine monoclonal antibody against envelope protein of Zika virus
CN111138534A (en) * 2019-12-31 2020-05-12 武汉班科生物技术股份有限公司 Mouse source monoclonal antibody of Zika virus envelope protein
WO2021227937A1 (en) * 2020-05-11 2021-11-18 神州细胞工程有限公司 Method for enhancing immunogenicity of protein/peptide antigen by means of forming fusion protein with modified fc fragment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1408875A (en) * 2001-09-29 2003-04-09 中国预防医学科学院病毒所 DNA type semliki forest cerebritis virus carrier for expressing IgG1 Fc chimeric protein as TNF receptor
CN102212139A (en) * 2011-03-29 2011-10-12 中国人民解放军第二军医大学 Fusion protein of tick-borne encephalitis virus envelop E protein and human antibody Fc fragment, and application thereof
CN103204943A (en) * 2013-03-20 2013-07-17 中国科学院武汉病毒研究所 Fusion protein of RSV (respiratory syncytial virus) protein F and Fc, and application thereof
WO2018064558A1 (en) * 2016-09-30 2018-04-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Zika virus vaccines
CN108290960A (en) * 2015-10-08 2018-07-17 艾伯塔大学理事会 Hepatitis C Virus E1/E2 heterodimers and its production method

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1408875A (en) * 2001-09-29 2003-04-09 中国预防医学科学院病毒所 DNA type semliki forest cerebritis virus carrier for expressing IgG1 Fc chimeric protein as TNF receptor
CN102212139A (en) * 2011-03-29 2011-10-12 中国人民解放军第二军医大学 Fusion protein of tick-borne encephalitis virus envelop E protein and human antibody Fc fragment, and application thereof
CN103204943A (en) * 2013-03-20 2013-07-17 中国科学院武汉病毒研究所 Fusion protein of RSV (respiratory syncytial virus) protein F and Fc, and application thereof
CN108290960A (en) * 2015-10-08 2018-07-17 艾伯塔大学理事会 Hepatitis C Virus E1/E2 heterodimers and its production method
WO2018064558A1 (en) * 2016-09-30 2018-04-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Zika virus vaccines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
YANG CHUNPENG ET AL.: "Characterization of two engineered dimeric Zika virus envelope proteins as immunogens for neutralizing antibody selection and vaccine design", 《JOURNAL OF BIOLOGICAL CHEMISTRY》 *
YANG CHUNPENG ET AL.: "Engineering of Fc Fragments with Optimized Physicochemical Properties Implying Improvement of Clinical Potentials for FC-Based Therapeutics", 《FRONTIERS IN IMMUNOOLOGY》 *
张晓光等: "埃博拉病毒重组膜蛋白Gp-Fc表达及免疫原性研究", 《病毒学报》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110981966A (en) * 2019-11-19 2020-04-10 广州迪澳生物科技有限公司 Fusion protein for detecting Zika virus and Zika virus specific T cell detection kit
CN111100201A (en) * 2019-12-31 2020-05-05 武汉班科生物技术股份有限公司 Murine monoclonal antibody against envelope protein of Zika virus
CN111138534A (en) * 2019-12-31 2020-05-12 武汉班科生物技术股份有限公司 Mouse source monoclonal antibody of Zika virus envelope protein
CN111138534B (en) * 2019-12-31 2021-09-28 武汉班科生物技术股份有限公司 Mouse source monoclonal antibody of Zika virus envelope protein
WO2021227937A1 (en) * 2020-05-11 2021-11-18 神州细胞工程有限公司 Method for enhancing immunogenicity of protein/peptide antigen by means of forming fusion protein with modified fc fragment

Similar Documents

Publication Publication Date Title
CN109705222A (en) The fusion protein and the preparation method and application thereof of flaviviridae envelope protein
CN105188745B (en) RSV F polypeptide before stabilized soluble fusion
US11034731B2 (en) Stabilized soluble pre-fusion RSV F polypeptides
JP6679475B2 (en) Stabilized soluble pre-fusion RSV F polypeptide
AU2021232702B2 (en) Stabilized pre-fusion RSV F proteins
CN108025057A (en) Stabilized virus I class fusion proteins
BR112021008975A2 (en) stabilized pre-fusion rsv f proteins
CN112638411A (en) Vaccine composition
WO2017207477A1 (en) Stabilized pre-fusion rsv f proteins
CN113736825B (en) Recombinant Drosophila cell line for expressing porcine atypical pestivirus fusion protein as well as preparation method and application thereof
CN117327174A (en) Humanized multivalent binding protein against novel coronaviruses and application thereof
WO2018175518A1 (en) Mini-protein immunogens displayng neutralization epitopes for respiratory syncytial virus (rsv)
CN116761624A (en) Stabilized coronavirus proteins and vaccine compositions thereof
OA19273A (en) Stabilized pre-fusion RSV F proteins.
OA17598A (en) Stabilized soluble pre-fusion RSV F polypeptides

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190503